Clinical Trial Update: Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study comparing radiopharmaceutical tracers Al18F-NOTA-LM3, 68Ga-DOTATATE, and 68Ga-NODAGA-LM3 for PET/CT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)
• 68Ga-NODAGA-LM3 (Gallium-68 NODAGA-LM3)
• Al18F-NOTA-LM3 (Al18F-NOTA-LM3)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING